2. Academic Validation
  3. Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression

Development of human cGAS-specific small-molecule inhibitors for repression of dsDNA-triggered interferon expression

  • Nat Commun. 2019 May 21;10(1):2261. doi: 10.1038/s41467-019-08620-4.
Lodoe Lama 1,  Carolina Adura 2,  Wei Xie 3,  Daisuke Tomita 4,  Taku Kamei 4,  Vitaly Kuryavyi 3,  Tasos Gogakos 1,  Joshua I Steinberg 1,  Michael Miller 4,  Lavoisier Ramos-Espiritu 2,  Yasutomi Asano 4,  Shogo Hashizume 4,  Jumpei Aida 4,  Toshihiro Imaeda 4,  Rei Okamoto 4,  Andy J Jennings 4,  Mayako Michino 4,  Takanobu Kuroita 4,  Andrew Stamford 4,  Pu Gao 3 5,  Peter Meinke 4,  J Fraser Glickman 6,  Dinshaw J Patel 7,  Thomas Tuschl 8
Affiliations

Affiliations

  • 1 Laboratory for RNA Molecular Biology, The Rockefeller University, 1230 York Ave, Box 186, New York, NY, 10065, USA.
  • 2 High-Throughput and Spectroscopy Resource Center, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA.
  • 3 Structural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA.
  • 4 Tri-Institutional Therapeutics Discovery Institute, 413 East 69th Street 16th Floor, New York, NY, 10021, USA.
  • 5 Key Laboratory of Infection and Immunity, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, Beijing, China.
  • 6 High-Throughput and Spectroscopy Resource Center, The Rockefeller University, 1230 York Avenue, New York, NY, 10065, USA. [email protected].
  • 7 Structural Biology Program, Memorial Sloan-Kettering Cancer Center, New York, NY, 10065, USA. [email protected].
  • 8 Laboratory for RNA Molecular Biology, The Rockefeller University, 1230 York Ave, Box 186, New York, NY, 10065, USA. [email protected].
PMID: 31113940 DOI: 10.1038/s41467-019-08620-4
Abstract

Cyclic GMP-AMP Synthase (cGAS) is the primary sensor for aberrant intracellular dsDNA producing the cyclic dinucleotide cGAMP, a second messenger initiating cytokine production in subsets of myeloid lineage cell types. Therefore, inhibition of the Enzyme cGAS may act anti-inflammatory. Here we report the discovery of human-cGAS-specific small-molecule inhibitors by high-throughput screening and the targeted medicinal chemistry optimization for two molecular scaffolds. Lead compounds from one scaffold co-crystallize with human cGAS and occupy the ATP- and GTP-binding active site. The specificity and potency of these drug candidates is further documented in human myeloid cells including primary macrophages. These novel cGAS inhibitors with cell-based activity will serve as probes into cGAS-dependent innate immune pathways and warrant future pharmacological studies for treatment of cGAS-dependent inflammatory diseases.

Figures
Products